Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.

In addition to our proprietary product pipeline, Halozyme has value-driving partnerships with leading pharmaceutical companies, including Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, and argenx for our ENHANZE® drug delivery technology, which enables biologics and small molecules currently administered intravenously to be delivered subcutaneously and may provide additional benefits. We are headquartered in San Diego.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.